Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient Women
← catalyst calendarSponsored by Pharmanutra S.p.a. (industry) · PHN.MI — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
146estimated
Sites
7
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-11 | actual | When the study began enrolling |
| Primary completion | May 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Anemia
- Iron Deficiency Anemia (IDA)
Interventions
- Dietary supplement: Sucrosomial® Iron (Sideral® Forte)
- Drug: Ferric Maltol (Feraccru®)
Primary outcome
what the primary-completion date above is the date OFHemoglobin normalization at week 12
measured Week 12 (End of Treatment)
Permalink · PHN.MI's whole pipeline · Catalyst calendar · Every registered study · What changed